Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05806749 · ClinicalTrials.gov registry record · Phase 1

Immunological Tolerance in Patients With Mismatched Kidney Transplants

A Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, sponsored by University of California, Los Angeles.

Active
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT05806749 is a Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 16 participants, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05806749, a Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, is active but no longer recruiting, sponsored by University of California, Los Angeles.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney and hematopoietic stem cell transplantation.

Conditions Studied

Chronic Kidney Diseases End-Stage Kidney Disease Kidney Transplant Failure and Rejection Immunological Tolerance

Interventions

  • COMBINATION_PRODUCT Donor CD34+, CD3+. and belumosudil

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2023-07-07
Est. Completion 2028-08
Phase Phase 1

Sponsor

University of California, Los Angeles

897 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05806749

The ClinicalTrials.gov registry entry for NCT05806749 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which Donor CD34+, CD3+. and belumosudil is the first listed.

NCT05806749 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05806749 about?

NCT05806749 is a clinical study titled "Immunological Tolerance in Patients With Mismatched Kidney Transplants". This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney an...

What is the current status of trial NCT05806749?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-07-07. Estimated completion is 2028-08.

What conditions does trial NCT05806749 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases, End-Stage Kidney Disease, Kidney Transplant Failure and Rejection, Immunological Tolerance.

What interventions are being tested in trial NCT05806749?

The interventions under investigation include: Donor CD34+, CD3+. and belumosudil (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05806749?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05806749 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Diseases

All registered trials for this condition

End-Stage Kidney Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.